AG真人官方

TORONTO and DALLAS, Aug. 28, 2025 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSX-V:听PINK) (OTCQX:听PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, today announced the appointment of Ted James, MD, MHCM, FACS, to the newly created position of Chief Medical Officer ("CMO").

In this fractional role, Dr. James will bring his clinical and leadership experience to help Perimeter strengthen its medical strategy and accelerate adoption of its technology. His perspective as a cancer surgeon and health system executive, combined with his experience in healthcare innovation, will support the company's growth as it advances toward commercialization.

Dr. James recently became System Physician Executive of the Endeavor Health Cancer Institute after serving as Chief of Breast Surgical Oncology and Director of the Breast Center at Beth Israel Deaconess Medical Center (BIDMC), where he oversaw the growth of a nationally accredited multidisciplinary breast program and developed an NIH-funded research portfolio. He was also Vice Chair of Academic Affairs in the Department of Surgery at BIDMC and an Associate Professor of Surgery at Harvard Medical School. Dr. James received his medical degree from Drexel University, completed his surgical residency at NYU (North Shore鈥揕ong Island Jewish), and trained in surgical oncology at Roswell Park Cancer Institute. He also holds a Master of Science in Healthcare Management from the Harvard T.H. Chan School of Public Health.

Dr. James said, "It is a privilege to join Perimeter at such a pivotal time. I have spent much of my career working on ways to improve breast cancer surgery, and margin assessment has always been a challenging problem to solve. What excites me about Perimeter is the chance to put a practical tool in the hands of surgeons that can make a real difference in the operating room. I am looking forward to helping the team bring this technology to the patients who need it."

"Dr. James brings a unique combination of clinical experience, research leadership, and insight into how care is delivered," said Adrian Mendes, Perimeter's Chief Executive Officer. "His expertise will be invaluable as we work to demonstrate the medical and practical value of our next-generation, AI-enabled Perimeter B-Series and advance it toward FDA approval."

About Perimeter Medical Imaging AI, Inc.

Based in Toronto, Canada and Dallas, Texas, (TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that has recently been evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month.

Perimeter B-Series OCT is limited by U.S. law to investigational use and not available for sale in the United States. Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. For more information, please visit .

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the Company's results for the three and six months June 30, 2025, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding management's views regarding the second quarter, the potential benefits of Perimeter S-Series OCT and Perimeter B-Series OCT and the expected benefits of Perimeter's updated version of its ImgAssist AI are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis and Annual Information Form for the year ended December 31, 2024, which are available on Perimeter's SEDAR+ profile at , and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.

CONTACTS:

Stephen Kilmer
Investor Relations
Direct: 647-872-4849
Email: [email protected]

Adrian Mendes
Chief Executive Officer
Toll-free: 888-988-7465 (PINK)
Email: [email protected]听

View original content to download multimedia:

SOURCE Perimeter Medical Imaging AI Inc.